What kind of interaction is it?

Caution: an interaction that may reduce efficacy or raise side-effect risk and warrants monitoring.

Is this interaction backed by published research?

Yes. NutriStack lists 2 citation rows for the Lithium Orotate + Olmesartan pair, each linking to PubMed by PMID where available. Full sourcing methodology at https://nutristackapp.com/methodology/interactions.

Interaction databaseSupplement × PrescriptionReviewed May 2026

Lithium Orotate and Olmesartan, a caution.

Q: Can I take Lithium Orotate and Olmesartan together?

Possibly, but with caution. Lithium Orotate and Olmesartan have a documented caution-tier interaction. Olmesartan blocks the AT1 receptor, reduces sodium reabsorption, and increases lithium retention by the kidney. Multiple case reports with ARBs describe lithium toxicity developing weeks after starting therapy, sometimes at previously safe lithium doses. Lithium Orotate doses are smaller but use the same renal pathway and the therapeutic window is narrow.

Q: How does this affect a NutriStack Stack Score?

-5 to your Stack Score per scored caution row.

Olmesartan blocks the AT1 receptor, reduces sodium reabsorption, and increases lithium retention by the kidney. Multiple case reports with ARBs describe lithium toxicity developing weeks after starting therapy, sometimes at previously safe lithium doses. Lithium Orotate doses are smaller but use the same renal pathway and the therapeutic window is narrow.

2 primary source citations. Moderate evidence. Last verified May 30, 2026.

Open the interaction checker →Read the methodology

One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.

Sourcing standards·Evidence tiers

From the interaction database

What the row says.

Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.

At a glance

Substances: Lithium Orotate and Olmesartan
Pair type: Caution
Evidence (highest tier): Moderate
Source citations: 2 sources
Stack Score effect: −5 to your Stack Score (per scored caution row).
Scope: Supplement × Prescription
Last verified: May 30, 2026

Caution · Moderate evidence

Caution

What is happening. Olmesartan blocks the AT1 receptor, reduces sodium reabsorption, and increases lithium retention by the kidney. Multiple case reports with ARBs describe lithium toxicity developing weeks after starting therapy, sometimes at previously safe lithium doses. Lithium Orotate doses are smaller but use the same renal pathway and the therapeutic window is narrow.

Mechanism. AT1 receptor blockade causes natriuresis and reduces GFR. Lithium reabsorption in the proximal tubule tracks sodium, so sodium loss and reduced filtration both raise fractional lithium reabsorption.

Recommendation. Avoid Lithium Orotate while taking olmesartan. If you must combine them, keep the dose low, stay well hydrated, and ask your prescriber to check serum lithium after 1-2 weeks. Hold the supplement during vomiting, diarrhea, or fever.

Sources (2)

Stack Score

How this pair moves the number.

Effect on the composite score

If both Lithium Orotate and Olmesartan are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).

The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.

Check your full routine

One pair was the worked example. NutriStack runs every pair in your stack at once.

Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.

Open the interaction checker →Browse the full research index